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 Abstract:  The  Kallikrein ( KLK ) gene locus encodes a family 
of serine proteases and is the largest contiguous cluster of 
protease-encoding genes attributed an evolutionary age 
of 330 million years. The  KLK locus has been implicated as 
a high susceptibility risk loci in numerous cancer studies 
through the last decade. The  KLK3 gene already has estab-
lished clinical relevance as a biomarker in prostate cancer 
prognosis through its encoded protein, prostate-specific 
antigen. Data mined through genome-wide association 
studies (GWAS) and next-generation sequencing point 
to many important candidate single nucleotide polymor-
phisms (SNPs) in  KLK3 and other  KLK genes. SNPs in the 
 KLK locus have been found to be associated with several 
diseases including cancer, hypertension, cardiovascu-
lar disease and atopic dermatitis. Moreover, introducing 
a model incorporating SNPs to improve the efficiency of 
prostate-specific antigen in detecting malignant states of 
prostate cancer has been recently suggested. Establish-
ing the functional relevance of these newly-discovered 
SNPs, and their interactions with each other, through  in 
silico investigations followed by experimental validation, 
can accelerate the discovery of diagnostic and prognostic 
biomarkers. In this review, we discuss the various genetic 
association studies on the  KLK loci identified either 
through candidate gene association studies or at the 
GWAS and post-GWAS front to aid researchers in stream-
lining their search for the most significant, relevant and 
therapeutically promising candidate  KLK gene and/or 
SNP for future investigations. 
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 Introduction
 Human genomic DNA is interspersed with many inter-
individual differences. These approximately 3 million 
variations, also called polymorphisms, are estimated to 
span around 0.1 % of the human genome (The Interna-
tional HapMap Consortium, 2007). The single nucleotide 
polymorphisms (SNPs) representing approximately 90 % 
of all sequence variations is the most common type of 
variation in the human genome (Collins et al. , 1998 ) with 
a frequency of  > 1 % in a given population. However, some 
researchers distinguish between  ‘ polymorphic SNPs ’ and 
 ‘ common SNPs ’ with a minor allele frequency of at least 
5 % in the population (Brookes , 1999 ; Kruglyak and Nick-
erson , 2001 ; Ladiges et al. , 2004 ). 
 Recent times have witnessed numerous candidate gene 
studies, which are restricted in the genes considered and 
the number of study subjects, and then whole-genome 
association studies (GWAS), making use of SNP arrays and 
elucidating various previously unknown disease-associ-
ated genes because of their unbiased advantage (Marian , 
2012 ; Kote-Jarai et al., 2011b). The GWAS technique is con-
stantly evolving, with efforts being made towards overcom-
ing previous drawbacks, such as population stratification, 
false positives and negatives, and replication difficulties. 
Moreover, recent access to next-generation sequencing 
platforms has revolutionized investigation in the field of 
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the detailed investigation of the  kallikrein gene locus and 
the genetic variants at this locus, and to uncover the func-
tional aspects of this disease-associated region. 
 The  KLK locus, which features among the seven 
highly-ranked susceptibility loci in a multi-stage prostate 
cancer GWAS (Kote -Jarai et al., 2008, 2011a ), is clustered 
in a tan dem array of approximately 300 kilobases (kb) 
on chromosome 19q13.4, and contains the largest cluster 
of 15 homologous protease genes (Lawrence et al. , 2010 ) 
said to have evolutionarily emerged 330 million years ago 
(Clements , 2008 ; Pavlopoulou et al. , 2010 ). With the recent 
imperative given to research on the  KLK gene locus, many 
significant gene  – disease associations have been estab-
lished and previously unknown roles of KLK proteins 
elaborated. Since the initial observation that the three clas-
sical  kallikreins  – human kallikrein 1 (hk1/KLK1), human 
kallikrein 2 (hk2/KLK2) and PSA  – are localized in this 
region, an additional 12 newly-discovered  kallikreins have 
been mapped to the KLK locus (Paliouras and Diamandis , 
2006 ). Their secreted extracellular nature makes the KLK 
proteins potential targets as biomarkers that can easily be 
analyzed by the well-established enzyme-linked immuno-
sorbent assay (ELISA) method. Apart from their importance 
as potential cancer biomarkers, their imprint has also been 
made in diseases like diabetes, skin disorders and neurode-
generative diseases (Paliouras and Diamandis , 2006 ). 
 We have reviewed the genetic architecture, genetic 
isoforms, function and the role of kallikreins in disease 
metastasis in previous articles (Tan Olivia et al. , 2006 ; 
Lawrence et al. , 2007, 2010 ). To the best of our knowledge, 
this article catalogs most of the identified SNPs within the 
KLK locus and reviews the role of these polymorphisms 
in various malignant and non-malignant diseases estab-
lished in the context of gene-association studies con-
ducted to date, with the objective of providing the reader-
ship with a consolidated resource on relevant SNPs in the 
 KLK locus for future disease association studies. 
 KLK SNP data-mining from SNPdb 
and 1000 Genomes 
 We assessed all the SNPs recorded within  ± 10 kb of 
the  KLK locus mapped in Genome Build GRCh37/hg19 
(chr19:51312404..51587502), from the most popular public 
database of SNPs, the National Center for Biotechnology 
Information ’ s dbSNP (Sherry et al. , 2001 ) build 132, using 
the UCSC web-browser ( http://genome.ucsc.edu/ ). From a 
total of 4331 polymorphisms identified within the  KLK locus, 
3420 (73.4 % ) were found to be SNPs and 911 (26.6 % ) were 
genetic biomarkers by sharply reducing the cost of whole 
human-genome sequencing (Mardis , 2008a,b ; Schuster , 
2008 ; Metzker , 2010 ; Davey et al. , 2011 ). The ultimate goals 
of these studies are to get a better understanding of the 
molecular mechanisms underlying a disease and to provide 
the foundation for the development of sensitive and readily 
applicable lab-based screening tools. Such tools will be 
useful for clinical diagnosis and monitoring of treatment 
and prognosis, and will thus assist clinicians to obtain 
a more accurate and reliable assessment of metastatic 
disease and hopefully support clinical decision-making. 
 The past few years have also seen an expansion in 
resources available to researchers, providing them with open 
access information and online data mining from the exten-
sive data accumulated through various international collab-
orative efforts. For example, the HapMap project provides a 
comprehensive SNP database, containing information on 
linked genomic regions (Olivier , 2003 ). The 1000 Genomes 
Project (Siva , 2008 ; Pennisi , 2010 ) is an international collab-
oration to sequence the genomes of a substantial number of 
individuals to provide a comprehensive resource on human 
genetic variation and their haplotype blocks. The 1000 
Genomes project ( http://www.1000genomes.org ), which 
is nearing completion, has already exceeded by half the 
number of novel SNPs observed by the HapMap project, i.e., 
with an estimate of more than 5.9 million variant nucleotide 
positions in the human genome. A total of 68 300 non-syn-
onymous SNPs were identified through the 1000 Genomes 
pilot project, 34 161 of which were found to be novel. A frac-
tion of these variations had been associated with various 
diseases and assigned a biological role, which is one step 
closer to establishing clinical relevance (Pennisi , 2010 ). For 
example, a particular 7 SNP risk profile may aid in the man-
agement of  BRCA2 mutation carriers in breast cancer (Anto-
niou et al. , 2010 ), and a combination of several validated 
 ‘ low-risk ’ SNP markers has been proposed to be useful in 
breast cancer and prostate cancer risk prediction (Pharoah 
et al. , 2008 ; Zheng et al. , 2008 ). 
 The protein-based indicator prostate-specific antigen 
(PSA), encoded by the  KLK3 gene at the  kallikrein (KLK) 
locus, is a well known and widely used oncogenic bio-
marker to diagnose and monitor prostate cancer progres-
sion after metastasis and treatment (Tan Olivia et al. , 2006 ; 
Lawrence et al. , 2010 ). It has accrued many critics since its 
use, however, mostly due to its non specificity and accu-
racy in establishing aggressive prostate cancer prognosis 
over possible benign tumors, and on the identification 
of set threshold levels to determine the need for invasive 
techniques such as biopsies (Prensner et al. , 2012 ), thus 
calling for a timely investigation to fine-tune the efficiency 
of PSA as a prostate cancer biomarker, possibly through 
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insertion/deletion polymorphisms (indels) and/or mixed 
type. A similar study was published by Goard et al., in 2007 
using custom designed tools  ‘ ParSNPs ’ and  ‘ LocusAnnotator ’ , 
which generated a catalog of 1856 polymorphisms of which 
1023 were validated (Goard et al. , 2007 ). While in our analysis 
a total of 2627 out of the 4331 polymorphisms were found to 
be validated (Nov, 2011) either by frequency, two-hit, submit-
ter, cluster or by HapMap, which includes 2535 SNPs and 92 
indels. (dbSNP uses certain validation methods to identify 
SNPs for their relevance. By frequency, where at least one 
submitted SNP in the cluster should have frequency data sub-
mitted; by cluster, which has two submissions with at least 
one submission assayed with a non-computational method; 
by submitter, with at least one submitter validated by inde-
pendent assay. By two-hit/two-allele signifies that all alleles 
have been observed in at least two chromosomes). Five-hun-
dred-seventy-four SNPs out of 2627 have recently been discov-
ered from the 1000 Genomes database (Siva , 2008 ; Pennisi , 
2010 ). A total of 2150 SNPs were shown to have a minor allele 
frequency (MAF)  > 1 % in the European population. 
 Our further analysis was restricted to validated poly-
morphisms only in an attempt to avoid analysis of false-
positive records in the dbSNP database that might have 
arisen due to sequencing artifacts. Based on the nature of 
their alleles, 1678 (66.2 % ) out of the 2535 validated SNPs in 
the  KLK locus (66.2 % ) were C → T transitions (or G → A on 
the opposite strand), and 464 (18.3 % ) were C → A (G → T on 
the opposite strand), while 234 (9.2 % ) and 148 (5.8 % ) were 
C → G and T → A transversions, respectively. The records for 
11 SNPs, which were reported to constitute more than two 
alleles, were not classified in the above groups. Considering 
the functional effects of SNPs based on their position to the 
nearest gene, and as defined by the UCSC browser, the most 
prevalent class annotations corresponded to those lying in 
non-coding intronic class (678/2535; 26.7 % ), untranslated 
region (113, 4.5 % ) and gene locus region polymorphisms 
(241, 9.5 % , present near the 3 ’ or 5 ’ of the gene). A smaller 
proportion of polymorphisms were associated with coding 
regions in the  KLK locus (97/2535; 3.8 % ), with 35 % syn-
onymous, 62 % missense and 3 % nonsense changes. The 
remaining polymorphisms not attributed to any position 
class by dbSNP (1406/2535; 55.4 % ) may refer to either inter-
genic or unannotated polymorphisms (Figure  1 ). 
 Functional  KLK SNPs:  in silico annotation 
 Functional SNPs are those polymorphisms that, depend-
ing on their position with respect to a protein coding region 
and/or a regulatory site, can affect the gene function and 
thus have a tendency to alter the cellular processes and 
functioning of the cell. Figure  2 details various web-based 
tools that can be used for the detailed  in silico prediction 
and analysis of potential functional roles of the  KLK SNPs. 
To this end, data for 1404 out of 2535 SNPs were retrieved 
using  ‘ FuncPred ’ ( http://snpinfo.niehs.nih.gov/snpfunc.
htm ) from the SNPinfo web-server ( http://manticore.niehs.
nih.gov/snpfunc.htm ), which assesses multiple functional 
prediction programs as well as calculating the regulatory 
potential score and conservation scores of SNPs (i.e., protein 
stability, splicing regulation, transcriptional regulation and 
post-translational modification), but lacking updated SNPs 
information from the 1000 Genomes project. Fourteen SNPs 
(rs11670728, rs12974899, rs12978483, rs2569522, rs2659056, 
rs28384475, rs3212811, rs3212840, rs3212846, rs3760739, 
rs58876874, rs7252452, rs3212850 and rs3745541) were pre-
dicted to alter a transcription-factor binding site. Nine SNPs 
(rs1624358, rs16988799, rs2736433, rs28384475, rs35192866, 
Non-coding intronic Coding UTR Near gene
Synonymous Missense Nonsense
Unclassified
 Figure 1   Position-based class annotations associated with validated  KLK polymorphisms in dbSNP as downloaded from the UCSC browser. 
 Note: As multiple transcript variants are known for each  KLK gene, the functional class annotations may vary based upon the transcript 
under consideration. In the current annotation, single nucleotide polymorphisms have been labeled on a preferential basis, e.g., coding 
region preferred over untranslated region (UTR), followed by intronic and near gene locations. 
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 Figure 2   An overview of some of the web-based tools used are represented relative to the single nucleotide polymorphism location in a 
gene (Figure adapted from Lee et al. , 2009b ). 
 Each single nucleotide polymorphism should be further examined for its functional effect with respect to each category (i.e., protein coding, 
splicing regulation, transcriptional regulation and post-translation) using a series of algorithms. 
rs61752567, rs7259651, rs10403407 and rs2659094) were 
predicted to alter the exonic splicing enhancer sites and 
disturb splicing regulation, while six might abolish the 
splicing domain itself. The PolyPhen ( http://coot.embl.de/
PolyPhen/ ) tool used by FuncPred (Adzhubei et al. , 2010 ) 
estimated the structural and functional impact of an amino 
acid substitution and predicted five SNPs to be deleterious 
(rs1048328, rs198977, rs5515, rs10422897 and rs183854). The 
SNPs3D software (http://www.snps3d.org; Yue et al. , 2006 ) 
was used to predict any deleterious effect of SNPs on protein 
function, which it does by making predictions based on the 
estimated impact of a non-synonymous SNP on protein sta-
bility, or considering conservation of the given amino acid 
within a protein family. Eleven SNPs (rs17632542, rs5515, 
rs198977, rs6072, 3733402, rs3733402, rs4253325, rs4253379, 
rs2569527, rs1048328 and rs183854) were predicted to be 
affirmative in their deleterious effect on protein functional-
ity by SNPs3D. Twenty-four SNPs were predicted to have a 
high conservation score of  > 0.4 and three SNPs (rs7245858, 
rs2691209 and rs16989073) to have a score of 1. 
 Another important class of functionally relevant 
SNPs are polymorphisms present at or near the micro-
RNA binding sites of functional genes (miRSNPs) with the 
potential to interfere with miRNA function, thus affecting 
gene expression (Pelletier and Weidhaas, 2010). Among 
the  KLK SNPs, four (rs10426, rs2691258, rs58682039 and 
rs61269009) were predicted to alter miRNA-binding sites, 
as predicted by Miranda ( http://www.microrna.org/
microrna/home.do ), while the Sanger method ( http://
www.mirbase.org/ ) predicted nine miRSNPs (rs2411334, 
rs2569735, rs2659092, rs268883, rs4846, rs9524, rs12151211, 
rs1654555 and rs2232539) within the KLK locus. 
 Functional  KLK SNPs: experimental 
validation 
 Apart from the various  in silico methods mentioned above, 
naturally-occurring polymorphisms identified in many 
human  KLK genes (e.g.,  KLK1, KLK2, KLK3 and  KLK12 ) 
have had their functional role established through labora-
tory investigation, as summarized in Table  1 . 
 KLK1 activity has previously been reported to 
decrease in people with primary hypertension and to 
be partly inherited, which led to the investigation of the 
association of  KLK1 exon 3 non-synonymous polymor-
phism Arg77His (dbSNP ID rs5515) with urinary  KLK1 
activity in hypertensive individuals (Slim et al. , 2002 ). 
Out of the 66 patients analyzed, five who were heterozy-
gous for the Arg77His polymorphism were seen to harbor 
statistically significant down-regulation of urinary KLK1 
activity.  In vitro functional analysis of the activity of the 
wild-type or polymorphic KLK1 protein confirmed this 
decreased activity in the presence of the histidine residue, 
and modeling using crystallographic data suggested this 
residue may alter substrate binding. The same labora-
tory performed a follow-up study of this finding in nor-
motensive subjects and confirmed the reduced activity in 
those carrying the histidine allele (Slim et al. , 2002 ). In 
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addition, the individuals heterozygous for Arg77His also 
showed inappropriate remodeling of the brachial artery, 
which suggested implications for cardiovascular disease 
(Azizi et al. , 2005 ). These studies support the finding 
of SNP rs5515 in the  in silico analysis mentioned above, 
which also predicted it to possibly be deleterious. Another 
 KLK1 coding SNP, Gln145Glu (rs5516), was not shown to 
affect urinary  KLK1 activity in this study (Slim et al. , 2002 ). 
Incidentally, a functional analysis in 1997 reported SNPs/
fragment length polymorphism in the promoter region of 
 KLK1 (between -133 and -121 with respect to the transcrip-
tion initiation site) to be associated with decreased  KLK1 
gene expression (Table 1; Song et al. , 1997 ). 
 KLK2 displays a common coding region polymor-
phism that substitutes Arg250 for a tryptophan residue 
(rs198977). Experimental analysis using recombinant 
KLK2 in insect cells revealed a lack of trypsin-like activity 
by the polymorphic KLK2 protein (Table 1; Herrala et al. , 
1997 ). The rs198977 SNP has also been shown to be asso-
ciated with significantly decreased levels of serum KLK2 
in two large studies (Nam et al. , 2003 ; Klein et al. , 2010 ), 
and our  in silico analyses in the last subsection indicated a 
possibly damaging/deleterious effect. This SNP has been 
the subject of much investigation in relation to prostate 
cancer risk and will be discussed later in this review. 
 The  KLK3 rs266882 SNP is one of the most interest-
ing functional SNPs in the context of prostate cancer sus-
ceptibility. Residing within one of the androgen response 
elements (AREs) of  KLK3 , ARE1, various studies have 
reported its association with increased serum PSA levels 
(Xue et al. , 2001 ; Medeiros et al. , 2002 ; Xu et al. , 2002 ; Rao 
et al. , 2003 ; Schatzl et al. , 2005 ). Functional studies on 
rs266882 attribute  KLK3 gene expression alteration to dif-
ferential binding of ARE1 to the androgen receptor (Table 
1) and enhanced transcriptional response to androgens. 
They also show increased prostate cancer susceptibility 
in the presence of A/A genotype (three-fold risk) and A/G 
genotype (2.4-fold risk; Lai et al. , 2007 ). 
 Vasilopoulos et al. investigated the  KLK7 3 ’ untrans-
lated region AACCins5874 insertion polymorphism for 
functional effects on  KLK7 expression and observed an 
increased expression in the presence of the insertion 
(Table 1; Vasilopoulos et al. , 2011 ), although no convinc-
ing association of this polymorphism with disease has 
been established to date. 
 The  KLK12 intronic c.457 + 2T > C polymorphism, i.e., a 
T to C substitution in the second nucleotide of intron 2, 
was claimed to be associated with a splicing abnormality 
(Table 1), with the expression of the human  KLK12 classi-
cal mRNA and the protein (hK12/KLK12) corresponding to 
the putative serine protease being absent in individuals 
with a c.457 + 2C/C genotype but not in individuals with the 
T/T or T/C genotypes (Shinmura et al. , 2004 ). However, 
the small number (n = 22) of samples considered in the 
analysis cells for replication in a larger set for results to be 
validated and conclusively confirmed. 
 Additional experimental studies are required to vali-
date the functional role of the SNPs shortlisted by the  in 
silico methods mentioned above. 
 Genetic architecture of the  KLK 
locus: haplotypes and tagging 
 Alleles of SNPs in close physical proximity to each other 
are often correlated, and can be represented as haplo-
types. Linkage disequilibrium (LD) is the occurrence of 
some combinations of alleles within a population more 
or less often than would be expected from a random 
formation of haplotypes from alleles (Devlin and Risch , 
1995 ). LD is represented by an r 2 or a D ’ value, which is 
calculated based on the difference between observed and 
expected allelic frequencies (assuming random distribu-
tions). Geneticists commonly use the threshold of r 2  > 0.8 
to measure which SNPs are in LD with other SNPs. To 
draw the LD map of the  KLK locus, we used the HapMap 
Public Release 27, Build 36 ( http://hapmap.ncbi.nlm.nih.
gov/cgi-perl/gbrowse/hapmap27_B36/#search ). All data-
base SNPs within the Centre d’Etude du Polymorphisme 
Humain (CEPH) population (Utah residents with ancestry 
from northern and western Europe) were plotted using the 
Haploview 4.2 software (http://www.broadinstitute.org/
scientific-community/science/programs/medical-and-
population-genetics/haploview/downloads; Barrett et al. , 
2005 ). 
 A total of 262 SNPs were genotyped in HapMap for a 
total of 205 individuals; 19 SNPs had a frequency of  < 0.01, 
and so were not included in haplotype analysis. A total 
of 33 LD blocks were identified for the 15  KLK genes, as 
shown in Figure  3 . A tag SNP is a representative of a group 
of SNPs in a region of the genome with high LD. Tag SNPs 
are useful in whole-genome SNP association studies 
(described in detail later) as it is then possible to confi-
dently predict genotypes for a number of different SNPs 
without assessing every SNP in a chromosomal region. 
The number of tagging SNPs within the KLK loci required 
to represent those HapMap SNPs with a frequency of  < 0.01 
was determined using the  ‘ Tagger ’ functionality with Hap-
loview by means of a pairwise analysis of LD with an r 2 
threshold of 0.8. Genotyping of 156 representative tagging 
SNPs is required to cover the 243  KLK variants based on 
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 Figure 3   Linkage disequilibrium map of the  KLK locus plotted using Haploview v4.2. 
 Data from the HapMap database European population was used. 
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a pairwise analysis of LD with an r 2 threshold of 0.8. As 
discussed above, the 1000 Genomes project is identifying 
many more genetic variants than those included in the 
HapMap database, and hence a vastly refined LD map of 
the  KLK locus can be produced when the data are released 
in a user-friendly format. 
 Recently, Parikh et al. (2010) generated a comprehen-
sive LD map of common SNPs and indels through deep 
sequencing analysis of a 56 kb region covering the KLK15 –
 KLK3 – KLK2 genes (chr 19: 56,019,829-56,076,043 bp; 
NCBI Build 36.3) in 78 unrelated individuals of European 
ancestry. A total of 555 polymorphic loci were identified, 
including 116 novel SNPs and 182 novel indels. Based on 
tagging analysis, 144 SNPs are necessary to tag the region 
at an r 2 threshold of 0.8 and MAF of 1 % or higher, while 86 
loci are required to tag all SNPs with a MAF  > 5 % . Further, 
these sequence data augment coverage of this region by 
only 35 % and 78 % compared to variants in dbSNP and 
HapMap, respectively. Thus, additional studies on LD 
mapping and tag SNP selection based on deep sequenc-
ing data are highly recommended. 
 Genetic association studies 
and  KLK SNPs 
 Numerous studies have been performed to investigate 
SNPs found in the  KLK genes for their malignant and 
non-malignant disease associations. The majority of 
SNP association studies have focused on their effects on 
cancer risk, particularly prostate cancer. Presumably, this 
was originally because of the identification of PSA/ KLK3 
in the etiology of this disease, and more recently because 
of results from large genome-wide studies implicating 
this locus in prostate cancer risk. Below we review the 
various SNP association studies carried out to determine 
disease susceptibility and the methods used to perform 
these analyses. The genotyping for the association studies 
was conducted on blood genomic DNA unless otherwise 
specified. 
 Association studies on low risk variants in 
KLK genes 
 Inherited genetic variants can be segregated into two 
categories: rare high-risk genetic variants (or mutations) 
and common low-risk genetic variants, such as SNPs. This 
review subsequently focuses on common, low-risk genetic 
variants or SNPs of the  KLKs and the genetic approaches 
used to identify these. While these SNPs have much 
weaker effects than high-risk genetic mutations, they are 
common and may have a large population attributable risk 
( > 5 % ) and together could contribute to a complex disease 
phenotype (Pestell , 2008 ). A complete and detailed list 
of SNPs analyzed in gene-association studies in previous 
research initiatives, including those that failed to reach 
statistical significance, has been included in the supple-
mentary tables. 
 Pre-GWAS KLK candidate gene-association 
studies 
 Prior to 2007, the candidate-gene approach was the pre-
dominant method used to explore inherited low-risk 
genetic variants. This approach is based on  a priori knowl-
edge about the gene(s) of interest in the pathogenesis of 
the phenotype and involves an examination of a relatively 
small number of genetic variants (between 1 and 100 
SNPs; Savage , 2008 ). The approach has led to the iden-
tification of a number of SNPs that may influence the risk 
of hormone-related cancers, particularly prostate cancer, 
with instances of ovarian cancer and breast cancer, as 
listed in Table  2 . 
 The most frequently analyzed  KLK SNP before 2008 
was rs266882 (G-158A) in the  KLK3 locus; a significant 
association with prostate cancer risk for this SNP was 
originally reported by Xue et al., in 2000 (Table 2). Numer-
ous subsequent studies have revealed conflicting results. 
Some have reported an association with the same allele 
as the original study (Gsur et al. , 2002 ; Medeiros et al. , 
2002 ; Cicek et al. , 2005 ; Lai et al. , 2007 ), while others 
have reported either a significant association in the oppo-
site direction (Chiang et al. , 2004 ; Binnie et al. , 2005 ) or 
no association for this SNP (Wang et al. , 2003 ; Salinas et 
al. , 2005 ; Mononen et al. , 2006 ; Severi et al. , 2006 ; Cun-
ningham et al. , 2007 ; Pal et al. , 2007 ; Penney et al. , 2011 ). 
A meta-analysis of all studies published up until 2008 
reported no evidence of association with prostate cancer 
risk overall (Supplementary Table 1; Jesser et al. , 2008 ). 
 Currently, significant associations have been reported 
for SNPs located within  KLK2 ,  KLK3 ,  KLK4 ,  KLK10 and 
 KLK15 with breast cancer, ovarian cancer survival and 
prostate cancer. Genes and significant SNPs of  KLK2 
(rs198977, rs2664155 and rs1506684),  KLK4 (rs806019), 
 KLK10 (rs3745535) and  KLK15 (rs266851) found to be asso-
ciated with cancer risk or prognosis are detailed in Table 
2. Information on subsequent studies, especially of those 
SNPs that failed to reach significance, can be found in 
Supplementary Table 1. 
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 Regarding the potential role of polymorphisms in non-
cancerous diseases,  KLK1 has been the most intensively 
studied  KLK gene, perhaps because it was the first  KLK gene 
to be discovered. Of the 13 different non-malignant diseases 
and traits investigated in  KLKs (Table  3 ), the role of  KLK1 
in cardiovascular and kidney-related diseases has been the 
focus of the majority of studies. A candidate gene associa-
tion study for the functional SNP rs5515 with risk of cardio-
vascular traits/disease did not report any association in the 
two small candidate SNP studies performed to date (Sup-
plementary Table 2). Perhaps the most compelling finding 
arose from research into hypertension in the Chinese Han 
population, with several  KLK1 polymorphisms indicating 
an increased cardiovascular traits/disease risk (Table 3, 
Supplementary Table 2; Hua et al. , 2005 ; Zhao et al. , 2007 ). 
Other examples of disease associations include  KLK4 for 
AIH IIA1,  KLK7 for atopic dermatitis, and  KLK8 for intra-
cranial aneurysm, details of which can be found in Table 3. 
A recent small cohort study (cases = 218 and con-
trols = 220) by Lee et al., performed pyrosequencing to 
genotype the SNP site ( + 255G > A, rs2664155) in intron 1 
of the  KLK2 gene. A statistically significant association 
between rs2664155 and male infertility (OR = 0.47, 95 % 
CI = 0.26 – 0.85,  p < 0.05) was reported (Lee and Lee , 2011 ), 
although no functional analysis towards this risk suscep-
tibility has been carried out to date. 
 Unless performed in a very large sample size from 
a well-characterized population, the candidate-gene 
approach is prone to spurious results. This is evident by 
the number of follow-up studies performed that have 
attempted to validate positive reports of  KLK polymor-
phism disease associations that have, however, failed to 
confirm original results (Supplementary Tables 1 and 2). 
 KLK genes in genome-wide association 
studies 
 Since around 2007, genetic epidemiology has been trans-
formed by the availability of high-throughput genotyping 
methods designed to provide an unbiased survey on the 
effects of common genetic variants, called GWAS. GWAS 
are studies wherein research subjects are typed for a large 
number of genetic variants, typically between 300 000 
and 1 000 000 polymorphisms, and the allele or genotype 
frequencies are evaluated for differences between groups 
(e.g., disease  vs. non-disease groups). The advantage of 
GWAS is that they allow for a wide search of genetic vari-
ants associated with disease without having to specify 
a particular gene of interest, facilitating the mining of 
potentially novel variants (Wellcome Trust Case Control 
Consortium , 2007 ). Due to the massive number of joint 
statistical tests performed, however, there is a higher level 
of type-1 error (false-positives). Statistical corrections 
for multiple hypotheses testing are therefore essential 
and a  p < 10 -7 has been proposed as an appropriate sig-
nificance level for evidence of a genome-wide associa-
tion (Thomas et al. , 2005 ). This means that large sample 
sizes are required for GWAS to ensure adequate statisti-
cal power to detect an association with small  p -values. 
Since the advent of GWAS technology, highly statistically 
significant and robust associations with SNPs in over 230 
diseases and traits have been successfully identified (Hin-
dorff et al. , 2011 ). The National Human Genome Research 
Institute maintains a catalog of published GWAS that can 
be accessed at http://www.genome.gov/gwastudies/. 
 A pioneering GWAS performed with 3268 cases and 
3366 controls identified a prostate cancer susceptibility 
locus between  KLK2 and  KLK3 . The minor allele of an SNP 
(rs2735839) in this region was reported to confer a 1.2-
fold decreased risk of prostate cancer (per allele odds 
ratio [OR] 0.83, 95 % confidence interval [CI]  = 0.75 – 0.91; 
 p = 1.5 × 10 -18 ; Table  4 ; Eeles et al. , 2008 ). Following this 
discovery, there have been a large number of studies 
pursuing association studies of SNPs in the  KLK region, 
examining both prostate cancer risk and prognostic 
features. The  KLK gene associations found to be signifi-
cant to prostate cancer susceptibility are summarized in 
Table 4, with non-significant associations mentioned in 
Supplementary Table 3. Relevant studies are discussed 
below. 
 The above GWAS-identified SNP, rs2735839, dis-
played a strong association with PSA levels (Table 4; 
Eeles et al. , 2008 ). However, there has been some debate 
as to whether this SNP is truly associated with prostate 
cancer or simply relates to PSA expression levels, since 
male controls used for the stage 1 analysis were limited 
to those with clinically low PSA levels ( < 0.5 ng/ml; 
Ahn et al. , 2008 ). Nevertheless, further investigation of 
rs2735839 in additional large case-control sample sets 
where controls were not screened for PSA levels did rep-
licate the association (Kote -Jarai et al., 2008 ). There have 
been several studies performed to find more such risk 
alleles, assessing the association of SNPs in the  KLK2 
and  KLK3 region with PSA and hK2/ KLK2 levels (Supple-
mentary Table 4). 
 An evaluation study was carried out by Bensen et al. to 
determine SNP associations with prostate cancer aggres-
siveness in Afro-American and European-American men 
from the North Carolina-Louisiana Prostate Cancer Project. 
Genotyped DNA from blood and buccal cell samples dem-
onstrated three SNPs in the KLK3 region (i.e., rs266870, 
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rs1058205 and rs2735839) showing significant associations 
with prostate cancer risk and significantly associating with 
PSA levels in Afro-American men (Bensen et al., 2012), as 
detailed in Table 4. 
 Even though no significant polymorphisms in  KLK4 
were identified relating to prostate cancer susceptibil-
ity, recent efforts by a multistage GWAS i.e., stages I and 
II of the Cancer Genetics Markers of Susceptibility Ini-
tiative have established gene interactions of rs2735839 
(taken as a conditioning SNP) with rs1558874, which is 
intronic to  PRRX2 ( p = 4.80E-5, multiplicative OR  = 1.33), 
and rs17714461 ( p = 7.14E-4) located 15 kb from  KLK4 and 
60 kb from the conditioning SNP, although not demon-
strating LD with it (r 2  < 0.001). Other notable interactions 
of rs2735839 were with rs17714461 (close to KLK4) and 
rs1558875, an intronic SNP to  PRRX2 , both SNPs being 
implicated in prostate cancer cell proliferation by previ-
ous studies (Ciampa et al. , 2011 ). 
 A study of the  KLK12 gene locus (cases = 3153 and 
controls = 3199) established an association between 
rs3865443, a SNP in  KLK12 having a marginal statistically 
significant association with prostate cancer risk, and 
a requirement for further validation in a larger sample 
group (Supplementary Table 3). 
 Another recent interesting finding was that  KLK14 was 
inversely androgen regulated in prostate cancer cells (Lose 
et al. , 2012 ). The potential of this gene in prostate cancer 
prognosis is promising, with the further identification of 
three SNPs around the  KLK14 locus being associated with 
prostate cancer aggression. The SNPs were rs17728459 
and rs4802765, located 9 kb and 2 kb upstream of  KLK14, 
respectively, and rs35287116, which encodes a p.Gln33Arg 
substitution in the  KLK14 signal peptide region (Lose 
et al. , 2012 ) listed in Table 4. 
 In the process of GWAS follow-up, our study of the 
 Prostinogen ( KLK15 ) gene identified rs2659056 to be 
associated with tumor aggressiveness in a Queensland 
(QLD) study cohort (cases = 1011 and controls = 1405). This 
was again confirmed in replicate sets of UK GWAS stage 
3 study. A highly significant association with Gleason 
score was observed in the combined analysis from dif-
ferent datasets (Table 4; Batra et al. , 2011a ). However, 
further experiments are needed to establish the func-
tional relevance of the RORalpha transcription-factor 
binding alteration predicted  in silico by the study (Batra 
et al. , 2011a ). 
 The intrinsic design of the GWAS means that sig-
nificantly associated SNPs are seldom those that are 
causally linked to the phenotype, and are instead in LD 
with a functionally important variant. Identification of 
the causal variant is important for understanding of the Ta
bl
e 3
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molecular mechanisms underlying the pathogenesis 
of disease. Moreover, sincere efforts are being made to 
include various  ‘ omics ’ levels from a systems biology 
viewpoint (Quigley and Balmain , 2009 ), epigenetic con-
siderations and gene-environment interactions to boost 
casual variant determination and also in the follow-up 
functional analysis of isolated SNPs in the post-GWAS 
era (Wang et al. , 2011 ). Consequently, additional inten-
sive studies are required to complement GWAS to iden-
tify disease-causing alleles and their functional role in 
pathogenicity, such as fine-mapping and imputation 
studies. 
 Fine-mapping studies on GWAS identified 
KLK SNPs 
 One method that can be used to identify causal SNPs 
involves the performance of fine-mapping studies. These 
involve examining the association of all known common 
sequence variants in the vicinity of the GWAS-identified 
SNP with the disease of interest. Appropriate common 
sequence variants may be identified by accessing SNP 
databases, using sequencing data from the 1000 Genomes 
project, or by performing re-sequencing studies of the 
region of interest. 
 As discussed previously, Parikh et al. (2010) per-
formed deep sequencing analysis of a 56 kb region 
flanking the GWAS-identified prostate cancer risk SNP 
rs2735839 in  KLK3 . Using these sequencing results, they 
then selected 24 SNPs to tag the region surrounding 
rs2735839 and geno typed these in five prostate cancer 
case-control studies from the US, France, Norway and 
Finland (cases = 3522 and controls = 3338; Parikh et al. , 
2011 ). While no strong association was observed with the 
original  KLK3 variant, rs2735839 ( p = 0.20), there was evi-
dence of an association of three highly-correlated SNPs 
(rs17632542, rs62113212 and rs62113214) with prostate 
cancer risk (rs17632542 per allele OR 0.7, 95 % CI  = 0.67 –
 0.89,  p = 3.41×10 -4 ). When stratified by disease aggressive-
ness, an association was only observed among less severe 
prostate cancer cases (Gleason score  < 7 and disease 
stage  < III). The rs17632542 SNP is potentially functional, 
introducing a non-synonymous amino acid change from 
isoleucine (hydrophobic) to threonine (polar) at position 
179 of the KLK3 protein. This amino acid is conserved 
in humans, chimpanzee and rhesus monkeys but not in 
other mammals or vertebrates. It is unclear whether this 
amino acid change has a benign or neutral functional 
impact and it is currently being investigated (Parikh 
et al. , 2011 ). 
 Imputation: a new tool for fine-mapping 
studies 
 Another method that can be used to refine GWAS signals 
and identify causal SNPs is imputation. Genotype imputa-
tion is the process of predicting (or imputing) genotypes for 
known variants that are not directly assayed in a sample 
of individuals. These ungenotyped variants can then be 
tested for association with the trait. Imputation involves 
the comparison of study samples genotyped for a rela-
tively large number of genetic markers (100 000 – 1 000 000 
SNPs) to a reference panel of haplotypes derived from a 
number of individuals genotyped at all markers of interest 
(Browning , 2008 ). To date, the HapMap database has typi-
cally served as this reference panel, with Phase II of this 
project (Frazer et al. , 2007 ) including over 3.1 million SNPs 
genotyped on four panels of individuals. Other reference 
panels, such as the 1000 Genomes project, have recently 
been made available. 
 A recent paper by Kote -Jarai et al. (2011a) undertook 
an imputation approach to refine the association between 
SNPs in the  KLK3 GWAS-identified region and prostate 
cancer. Using genotyping data from a two-stage GWAS 
using British and Australian samples (Eeles et al. , 2009 ) 
and the Cancer Genetic Markers of Susceptibility study 
( http://www.cgems.cancer.gov/ ), genotypes were imputed 
for 197 and 312 SNPs from HapMap Phase II and the 1000 
Genomes project, respectively. Interestingly, the same 
previously unreported SNP identified in the fine mapping 
study by Parikh et al., in 2011, rs17632542, was also found 
to be strongly associated with prostate cancer risk in 
this study. The association was subsequently confirmed 
by direct genotyping of 10 405 cases and 10 681 control 
individuals from the three stages of the British/Austral-
ian GWAS. This association remained strong after adjust-
ing for the GWAS-identified SNP rs2735839 (  p = 8.5 × 10 -14 ). 
The authors suggest rs17632542 to be the most plausible 
functional variant and multiple molecular dynamic sim-
ulations revealed that the threonine variant displayed 
superior stability in solution with likely displacement 
of the kallikrein loop (Kote -Jarai et al., 2011a ). The func-
tional consequences of these  in silico findings are yet to 
be established. 
 Aside from prostate cancer, the  KLK locus has not 
specifically been identified by GWAS to be associated 
with any other disease or trait. Coverage of genetic vari-
ation in the  KLK locus by the genotyping chips used in 
these studies is quite poor, however, ranging from just 
6 % of the SNPs in the  KLK9 gene to 55 % in the  KLK14 
gene (Lose and Batra, unpublished data). Hence, more 
comprehensive and targeted investigations of SNPs in 
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the  KLK locus and various diseases are still warranted. 
In addition, the majority of GWAS studies have been 
performed in Caucasian subjects, thus genome-wide 
studies of Asian and African/African-American popula-
tions may yet reveal or confirm a role for the  KLKs in 
other diseases. 
 Association studies on high-risk 
variants in KLK genes 
 Rare genetic variants are considered to have a larger 
phenotypic effect on disease risk. As lethal variations are 
not favorable to propagation through natural selection, 
many of these have been identified using family-based 
studies (Marian , 2012 ). Rare variants were commonly 
overlooked in GWAS analysis due to their inability to reach 
statistical significance relative to other common variants. 
Thus there was a conceptual shift of hypothesis from 
common disease to common variant (CD – CV) to rare vari-
ants to common disease (RV – CD). This has been guiding 
next-generation sequencing measures to direct focus 
towards high-risk variants in order to establish complex 
disease associations (Marian , 2012 ). 
 Only one  KLK gene,  KLK4 , has successfully been iden-
tified as containing a high-risk, disease-causing muta-
tion. Amelogenesis imperfecta (AI) – hypomaturation type 
IIA1, as listed in Table 3, is a disorder of the teeth that 
results from incomplete mineralization of tooth enamel. 
 KLK4 was shown to be one of several factors critical for 
normal enamel formation (Simmer and Hu , 2002 ) and was 
therefore investigated for mutations in AI families. The 
initial study identified a truncating mutation, p.W153X, 
in one AI family that occurs at a highly conserved tryp-
tophan residue and results in a KLK4 protein lacking the 
S207 residue of the catalytic triad (Hart et al. , 2004 ). Two 
further AI studies carried out using DNA from blood and 
saliva samples have identified several more Caucasian 
families carrying this mutation (Wright et al. , 2009, 2011 ), 
cementing  KLK4 as a high-risk gene for this condition. 
 Conclusions 
 Genetic variation in the  kallikrein genes has been a popular 
focus for human disease research since their discovery. Ini-
tially, many conflicting results were observed, a pheno-
menon typical of candidate gene studies at the time. Since the 
advent of genome-wide association studies involving large 
numbers of patients and controls, quite promising results 
have arisen, particularly those implicating SNPs around  KLK2 
and  KLK3 in prostate cancer risk. Although it is not likely that 
 KLK SNP(s) alone will be useful in a clinical setting without 
the incorporation of SNPs from other loci and/or additional 
variables, particular  KLK SNPs may one day form part of 
rapid, germline DNA-based clinical tests that may be able to 
stratify patients at a high risk of developing prostate cancer 
from those with a very low prostate cancer risk. 
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